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SUMMARY. To study the relationship between antibod-
ies detected in patients and/or donors sera and the
clinical features of acute non-haemolytic transfusion
reactions (ANHTRs), and to determine any gender-
related difference. ANHTRs range from urticaria to
transfusion-related acute lung injury (TRALI). Anti-
bodies to human leukocyte antigen (HLA), granulo-
cytes, platelets, and/or plasma proteins are implicated
insomeoftheANHTRs.Ahigherantibodypositivityis
expected for females than for males. A comparative
study of ANHTRs for antibody positivity and their
clinical features between females and males for both
patients and donors is helpful for characterizing
ANHTRs including TRALI more clearly, but such
studiesarefewandoutdated.Twohundredandtwenty-
three ANHTR cases reported by 45 hospitals between
October2000andJuly2005wereanalysed.Thepatients
and196donorsofsuspectbloodproductswerescreened
for antibodies to HLA Class I, HLA Class II, gran-
ulocytes, and platelets. The patients were also screened
for anti-plasma protein antibodies. The types and
severityofANHTRdidnotdiffersignificantlybetween
femaleandmalepatients.Thefrequencyoftheanti-HLA
antibodies, but not that of the non-HLA antibodies, was
significantly higher in females. Non-HLA antibodies
were significantly associated with severe reactions in
females. All the TRALI cases had predisposing risk
factors for acute lung injury, and 60% of the cases
showed anti-leucocyte antibodies. Although the anti-
HLAantibodiesweredetectedmorefrequentlyinfemales
than males, no significant association of ANHTRs
including TRALI with gender, not only for patients,
but also for donors, could be shown in this study.
Key words: acute non-haemolytic transfusion reaction,
anti-granulocyte antibody, anti-HLA antibody, anti-
plasma protein antibody, anti-platelet antibody,
TRALI.
Acute non-haemolytic transfusion reactions
(ANHTRs) comprise frequently occurring adverse
transfusion events, ranging from mild urticaria to
transfusion-related acute lung injury (TRALI)
(Combs et al., 2002; Domen & Hoeltge, 2003; Gilstad,
2003; Klein & Anstee, 2005). After the transmission
risk of infectious agents has been considerably
reduced, ANHTRs have become the most important
issues in transfusion safety (Domen & Hoeltge, 2003;
Gilstad, 2003; AuBuchon, 2004). In fact, the number
of ANHTR cases reported voluntarily by hospitals to
the Japanese Red Cross Society Blood Service (JRC)
haslinearlyincreased,from422in1995to1609in2004
(JRC Transfusion Information 9606-25, 0509-91).
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proteins have been implicated as causative agents of
some ANHTRs. TRALI, one of the leading causes of
transfusion-related deaths, has been most intensively
investigated. However, the reported incidence of
TRALI and involvement of antibodies show major
discrepancies among related studies owing to incon-
sistentdiagnosticcriteria(Sillimanetal.,2003;Kleinman
et al., 2004; Bux, 2005). Post-transfusion respiratory
reaction can be caused not only by TRALI, but also by
other entities such as anaphylactic reaction and trans-
fusion-associated circulatory overload (TACO), sug-
gesting that there are borderline cases between TRALI
and other ANHTRs (Bux, 2005; Rana et al.,2 0 0 6 ) .A
comparative study of a wide range of ANHTRs,
including screening for antibodies will be helpful to
characterize TRALI more clearly. However, few such
studies have beenreportedand they tendto be outdated
(Barton, 1981; Decary et al., 1984; de Rie et al., 1985).
These concerns prompted us to undertake this study.
The Hyogo Red Cross Blood Center (HBC) is
a regional blood centre of the JRC, which provides all
blood components to hospitals in Hyogo Prefecture
with a population of 5 6 million people (4 4% of
Japans population). It is estimated that about 50 000
patients receive transfusions annually. ANHTR cases
reportedbyhospitalstotheHBChaveincreased, from
32 cases in 2000 to 63 cases in 2004. Our objective was
to study the relationship between antibodies detected
in the patients or donors sera and the clinical features
of ANHTR. For this purpose, we screened antibodies
to human leukocyte antigen (HLA) Classes I, and II,
granulocytesandplateletsinbothpatientsanddonors.
In addition, patients were screened for antibodies to
plasma proteins.
We determined the frequency of antibodies and
the relationships between antibodies and ANHTRs,
including TRALI. As higher frequency of antibodies
can be expected for females, we intended to determine
the differences between the results for females and
males, not only for patients but also for donors.
MATERIALS AND METHODS
Hospitals
Transfusion reactions were reported to the HBC on
a voluntary basis by 45 hospitals located in Hyogo
Prefecture during the study period from October 2000
to July 2005.
Patients
Twohundredandtwenty-threepatients(92femalesand
131males)withANHTRreportedfromthe45hospitals
between October 2000 and July 2005 were analysed.
Patients age,sex,disease,history oftransfusion and/or
pregnancyandhistoryofprevioustransfusionreactions
as well as clinical features of the transfusion reaction
were reported on the JRC reporting form.
Blood products
Blood components involved in this study were red
blood cell concentrates (RCC), platelet concentrates
(PC), and fresh-frozen plasma (FFP).
Types of blood donation were 200 or 400 mL of
whole blood and apheresis of platelets or plasma. A
blood component equivalent to the amount in 200 mL
of whole blood has been defined as 1 unit by the
JRC. For RCC, red blood cells were suspended in a
mannitol–adenine–phosphate solution after centrifu-
gation.AllPCswerederivedfromsingledonorapheresis.
FFPof1unit(around80mL)or2units(around160mL)
was derived from whole blood, whereas FFP of 5 units
(around 450 mL) was derived from single donor
apheresis. Regardless of the type of blood component,
every bag was derived from a single donor.
Evaluation of transfusion reactions
ANHTR developing within 24 h after transfusion were
evaluated and classified into seven types: Allergy, Ana-
phylactoid, Anaphylaxis, Febrile, Sepsis-like, TRALI
and Dyspnoea unclassified.
Allergy is the mildest and consists of skin symp-
toms such as urticaria and pruritus without change in
vital signs. Anaphylaxis consists of severe hypoten-
sion, syncope, or dyspnoea caused by respiratory tract
obstruction. Anaphylactoid consists of allergic reac-
tions with intermediate severity between allergy and
anaphylaxis.
Febrile reactions were classified into Febrile or
Sepsis-like. Sepsis-like is severe reaction meeting
with the criteria of BaCon Study (fever  39 Co r
 2 C increase, rigors, tachycardia  120 b min
21 or
 40 b min
21 increase or change in systolic blood
pressure  30 mmHg rise or drop) (Roth et al., 2001)
with negative bacterial culture both in patients blood
and in suspected blood components. Not so severe
febrile reactions were classified into Febrile.
Post-transfusion respiratory reactions not typical to
anaphylaxis were further evaluated based on chest
radiographic and clinical data. Pulmonary oedema
without signs of circulatory overload was classified
into TRALI. Pulmonary oedema should be bilateral,
except for patients whose functional lung was unilat-
eral. Otherwise, the post-transfusion respiratory re-
actions were classified into Dyspnoea unclassified.
456 S. Imoto et al.
# 2007 The Authors
Journal compilation # 2007 British Blood Transfusion Society, Transfusion Medicine, 17, 455–465Accordingly, Allergy, Anaphylactoid and Febrile
were considered as non-severe reactions, whereas
Anaphylaxis, Sepsis-like and TRALI were considered
as severe reactions. Severity was not determined for
Dyspnoeaunclassified,asthiscategoryincludessevere
and non-severe reactions.
Screening for antibodies
Sample collection from patients and donors. Patients
sampleswereobtainedfromphysiciansafterobtaining
informed consent. Donors samples were prepared
from suspect blood products in the segment tubes
obtained from physicians. Simultaneously prepared
plasma components were also examined when avail-
able and TRALI was suspected. Before antibody
detection, donors plasma sample was defibrinated
by the treatment with thrombin and calcium chloride.
Antibodies to HLA antigens. The Enzyme-Linked
ImmunoSorbent Assay (ELISA) method (Lambda
Antigen Tray (LAT); One Lambda, Inc., Canoga
Park, CA, USA) was used from October 2000 to
September 2004 and the Luminex technology (LAB-
Screen PRA
; One Lambda) from October 2004 to
July 2005, according to the manufacturers instruc-
tions. LAT-M was used for screening and when the
reaction was positive, specificity of the antibody was
determined using another panel antigen tray, LAT-
1240. For the Luminex technology, after incubation
with colour-coded beads (LABScreen PRA
 Class I
and Class II), fluorescent emission from the beads was
detected and analysed with the Luminex 100 IS
System (Luminex Corporation, Austin, TX).
Antibody to granulocyte antigens. The anti-granulocyte
antibody was detected witht h em i c r o - m i x e dp a s s i v e
haemagglutination method (MPHA) using extracted
granulocyte antigens (EG-MPHA) as previously re-
ported(Arakietal.,1999).Briefly,Mono-PolyResolving
Medium(DainipponPharmaceuticalCo.,Osaka,Japan)
was used to isolate granulocytes from heparin-anti-
coagulated fresh blood from six volunteer donors. More
than 90% of the granulocytes consisted of neutrophils.
Next,3 10
3/mLofgranulocyteswassuspendedinsaline
containing 3% sucrose, left standing for 3 days at 4 C,
andcentrifugedat10000  gfor5 min.Thesupernatant
w a st h e np l a c e di na7 2 - w e l lU - t y p eT e r a s a k ip l a t e
(Robbins Scientific Co., Sunnyvale, CA, USA) and left
standing overnight at 4 C. The antigen-coated tray was
storedat280Cuntiluse.Afterthawingandrinsing,the
test serum was placed in the wells and left standing
overnight at 22 C in a humidified chamber. After
washing, anti-human immunoglobulin-labelled sheep
blood cells were added and left standing in a humidified
chamber for 4 h at 22 C. The reactivity was detected by
observing the distribution pattern of the erythrocytes.
To detect anti-granulocyte antibodies in HLA
antibody containing serum, an antigen-coated tray
prepared as described above was treated with chloro-
quine to inactivate HLA Class I antigens as described
previously (Araki et al., 1999).
Antibodies to platelet antigens. Screening for anti-
platelet antibodies was performed with the aid of an
anti-Human Platelet Antigen (HPA)-MPHA panel
(Olympus, Tokyo, Japan) according to the manu-
facturersinstructions.Thereactivitytoextractedplatelet
antigens was measured by the MPHA (Shibata et al.,
1986). For the detection of anti-platelet antibodies in
HLAantibodypositiveserum,thepanelplatewastreated
with chloroquine to inactivate HLA Class I antigens in
accordance with the manufacturers instructions.
Antibodies to plasma protein and screening for serum
protein deficiency. Antibodies to IgA, C4, C9, hapto-
globin, ceruloplasmin, alpha2 macroglobulin and
beta2 glycoprotein I were detected by ELISA as
described previously (Shimada et al., 2002), and their
presence was confirmed by Western blot analysis
(Shimadaetal.,2002).For screeningforserum protein
deficiency, each plasma protein concentrations were
measured by means of peak-rate nephelometry (Array
360 System, Beckman Coulter K.K., Tokyo, Japan).
Proteins with a concentration below the range detect-
able by nephelometry were measured with a highly
sensitive ELISA method (Shimada et al., 2006).
Statistical analysis
To determine the significance of differences between
two groups, we used the w
2 test for 2   2 comparisons
and Fishers exact test for 2   7 comparisons with
alpha level equal 0 05 (Tables 2–4). P < 0 05 was
considered significant. STATA version 8 2 (Stata-
Corp,CollegeStation,TX,USA)wasusedtocalculate
all relevant values.
RESULTS
Patients characteristics
The characteristics of the 223 patients included in this
study are shown in Table 1. The gender ratio was
similar to the overall ratio for transfusion recipients,
45 : 55 (42 221 females and 51 128 males), according to
the annual data of Tokyo Metropolitan Government
(Tokyo Metropolitan Government, 2004). The mean
ages and age distributions of the patients were similar
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and male patients had haematological diseases. The
history of previous transfusion and/or pregnancy was
recorded for 76 (83%) of the female patients, with 34
(45%) having a history of both. The history of
previous transfusion was recorded for 101 (77%) of
the male patients.
Features of ANHTRs of patients
The reaction types of the 223 ANHTR patients are
shown in Table 2. The distribution of reaction types
did not significantly differ between females and males
(P ¼ 0 526, Fishers exact test). Eleven of the 223 cases
of ANHTRs were attributed to multiple blood
components. Of the remaining 212 cases, 49% were
attributed to PC, 42% to RCC and 9% to FFP.
Antibodies detected in patients
Theseraofallthepatientswerescreenedforantibodiesto
HLA Class I, HLA Class II, granulocytes, platelets and
plasma proteins. The positivity rate for antibodies was
higher for the female patients (43%) than for the male
patients (24%) (P ¼ 0 00177) (Table 3). The antibody
positivity rate associated with Anaphylactoid of the
female patients was significantly higher than that of the
male patients (P ¼ 0 001, Fishers exact test with
Bonferroni correction). Febrile and Sepsis-like types
showed the same tendency (P ¼ 0 086 and P ¼ 0 067,
respectively). The antibodies detected in each case are
shown in Fig. 1. The positivity rate for anti-HLA
antibodies for the female patients (36%, 33/92) was
significantly higher (P ¼ 0 00005) than that for the male
patients (13%, 17/131). Of the 33 anti-HLA-antibody-
positive female patients, nine (27%) had an antibody to
HLAClassI,three(9%)hadanantibodytoClassII,and
21 (64%) had antibodies to both HLA Classes I and II.
For the 17 antibody-positive male patients, the corres-
pondingdatawereeight(47%),one(6%)andeight(47%).
The positivity rates for the anti-granulocyte anti-
bodywere13% (12/92)forthe femalepatientsand7%
(9/131) for the male patients (P ¼ 0 1202). Those for
the anti-platelet antibody were 9% (8/92) for the
female patients and 5% (6/131) for the male patients
(P ¼ 0 2123).
The positivity rates for the anti-plasma protein
antibodies were similar between the female and male
Table 1. Characteristics of Patients with ANHTR
Gender Number
Age
Diseases* History of transfusion/pregnancy
Mean (range) Haematol Non-haematol Yes No Unknown
Female 92 54 2 (5–94) 51 (55%) 41 (45%) 76 7 9
Male 131 53 0 (0–94) 67 (51%) 64 (49%) 101 17 13
*Diseases: haematol, haematological diseases; non-haematol, diseases other than haematological diseases.
Table 2. Reaction types in female and male patients
Gender
Non-severe Severe
Dyspnoea unclassified Total Allergy Anaphylactoid Febrile Anaphylaxis Sepsis-like TRALI
Female 26 21 14 17 2 1 11 92
Male 42 29 27 15 4 4 10 131
Total 68 50 41 32 6 5 21 223
Table 3. Reaction types and incidence of antibodies in female and male patients
Gender
Non-severe Severe
Dyspnoea
unclassified Total Allergy Anaphylactoid Febrile Anaphylaxis Sepsis-like TRALI
Female 30 8% (8/26) 66 7% (14/21) 57 1% (8/14) 29 4% (5/17) 100% (2/2) 100% (1/1) 18 2% (2/11) 43 5% (40/92)
Male 19 0% (8/42) 20 7% (6/29) 25 9% (7/27) 40% (6/15) 0% (0/4) 25% (1/4) 30% (3/10) 23 7% (31/131)
Total 23 5% (16/68) 40% (20/50) 36 6% (15/41) 43 8% (14/32) 33 3% (2/6) 40% (2/5) 23 8% (5/21) 31 8% (71/223)
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Of the 21 anti-plasma protein antibody positive
cases, 18 (86%) showed allergic reactions (Allergy,
AnaphylactoidorAnaphylaxis).Twoofthethreeanti-
haptoglobin-positive patients were haptoglobin defi-
cient, as reported elsewhere (Shimada et al., 2006;
Shimode et al., 2006). Except for these two cases, none
of the anti-plasma protein antibody positive cases
showed plasma protein deficiency.
Of the 40 antibody-positive female patients, eight
showedseverereactions(fiveAnaphylaxis,twoSepsis-
like and one TRALI). Of these eight patients, seven
(87 5%) showed positivity for antibodies other than
HLA (non-HLA antibodies: five anti-granulocyte
antibody and two anti-plasma protein antibody).
However, only 46 7% (14/30) of the patients with
non-severe reactions showed such positivity (P ¼
0 0388). For the male patients, no significant differ-
ence was observed. Among the 31 antibody-positive
male patients, six (75%) of the eight patients with
severe reactions and 16 (80%) of the 20 patients with
non-severe reactions showed non-HLA antibodies.
Features of ANHTRs and associated donors
One hundred and ninety-six donors of blood compo-
nents associated with 134 ANHTR cases were
examined. The blood components consisted of 85
RCCs, 57 PCs and 54 FFPs (Table 4). The relatively
higher ratio of FFPs was because of the inclusion of
patients who were transfused with multiple units of
blood components. Of the 196 donors, 67 (34%) were
female and 129 (66%) were male. Because the donors
gender ratio differed depending on the type of blood
donation (Blood Products Research Organization,
Annual Report 2001–2005), the expected values
calculated from the annual donation data were 32%
female and 68% male, which are almost similar to the
actual data.
Thedistributionofassociatedreactiontypesshowed
no significant difference between the female and male
donors(Table 4)(P¼0 304,Fishersexact test).Fifty-
one donors were associated with severe reactions (30
Anaphylaxis, 6 Sepsis-like and 15 TRALI), of whom
21 were female (21/67, 31 3%) and 30 were male
(23 3%, 30/129) (P ¼ 0 221).
Antibodies detected in donors
The antibodies detected in the donors are shown in
Fig. 2. Of the 196 donors, 32 (16%) donors were
antibody-positive, of whom 15 were female (15/67,
22%) and 17 were male (17/129, 13%) (P ¼ 0 09799).
ThepositivityratesforantibodiestoHLAClassIand/
orClassIIwere15%(10/67)forthefemaledonorsand
5% (7/129) for the male donors (P ¼ 0 025). The
corresponding results for the anti-granulocyte anti-
body were 8 and 7% and those for the anti-platelet
antibody were 4 and 2%. Although the positivity rates
for anti-HLA antibodies were significantly higher for
thefemaledonors,thoseforantibodiestogranulocytes
and platelets showed no significant difference between
the female and male donors.
Concerningseverity,threeofthe15(20%)antibody-
positive female donors were associated with severe
reactions (Anaphylaxis). All three showed positivity
for the non-HLA antibodies (two, anti-granulocyte
antibody; one, anti-platelet antibody); however, only
three of the 11 donors (27 3%) associated with non-
severe reactions had non-HLA antibodies (P ¼
0 0241). However, three of the 17 (17 6%) antibody-
positive male donors were associated with severe
reactions. Two of the three donors (66 7%) associated
with severe reactions had non-HLA antibodies,
whereas eight of the 13 donors (61 5%) associated
with non-severe reactions had non-HLA antibodies.
Although the positivity rate for the non-HLA anti-
bodies was significantly higher in the female donors
Table 4. Reaction types and donors gender of suspect blood component
Non-severe Severe
Dyspnea-
unclassified Total Allergy Anaphylactoid Febrile Anaphylaxis Sepsis-like TRALI
Number of cases 35 35 20 18 5 3 18 134
Suspect FFP 5 FFP 25 FFP 8 FFP 11 FFP 5 FFP 54
Blood components RCC 13 RCC 14 RCC 15 RCC 10 RCC 6 RCC 9 RCC 18 RCC 85
PC 20 PC 15 PC 6 PC 9 PC 1 PC 6 PC 57
Donors gender
Female 10 14 14 13 3 5 8 67
Male 28 40 15 17 3 10 16 129
Total 38 54 29 30 6 15 24 196
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ated with non-severe reactions, it was not the case in
male donors.
Analysis of TRALI cases
The characteristics of 26 patients with post-transfu-
sion respiratory reactions not typical to Anaphylaxis
were analysed. Chest radiographic data were available
for only 15 of the 26 patients. Of these 15 patients,
seven showed pulmonary oedema and/or congestive
shadow. The remaining eight patients showed no signs
of pulmonary oedema and were classified as having
Dyspnoea-unclassified. Fivepatientswereclassifiedas
having TRALI (Table 5). Although pulmonary
oedema was unilateral owing to congenital anomaly
of one lung, patient 5 otherwise met the TRALI
criteria and was classified as having TRALI. All the
five patients showed risk factors for acute lung injury
(two cardiac surgery, two pneumonia and one sepsis)
before transfusion. Regarding the remaining two
patients, TACO was suspected in one, and anaphylac-
ticreactionwasconsideredasmorelikelyfortheother.
Both patients as well as the 11 patients without
available chest radiographic data were classified as
having Dyspnoea-unclassified.
For the five TRALI patients, the involvement of 23
blood components was suspected; seven components
Severity
Type of
reaction HLA I HLA II Granulo Platelet Protein Severity
Type of
reaction HLA I HLA II Granulo Platelet Protein
a2
C4
a2
a2
hapt
C4
celps
a2
C9
celps
a2, C4
C9
IgA, a2
celps, a2
latex
a2
C9
Sepsis-like
hapt TRALI
beta2
C9
hapt
TRALI
Dyspnoea unclassified
Anaphylaxis
Febrile
Dyspnoea unclassified
Severe
Anaphylaxis
Sepsis-like
Female patients  Male patients
Non-
severe
Allergy
Non-
severe
Allergy
Anaphylactoid
Anaphylactoid
Febrile
Severe
Fig. 1. Antibodies detected in female and male patients. Each horizontal row shows the screening result for one patient. Grey
cells indicate that the antibody was positive and non-coloured cells indicate that the antibody was negative. HLA-I, anti-HLA
Class I antibody; HLA-II, anti- HLA Class II antibody; granulo, anti-granulocyte antibody; platelet, anti-platelet antibody;
protein, anti-plasma protein antibody; a2MG, anti-alpha 2 macroglobulin; b2GP, anti-beta2 glycoprotein I; celps, anti-
ceruloplasmin; hapt, anti-haptoglobin.
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(69 6%) from the male donors (Table 5). Three
patients (patients 1, 2 and 5) showed positivity for
anti-HLA and/or anti-granulocyte antibodies. For
patient 1, seven RCCs and five FFPs were transfused
during and after coronary artery bypass graft surgery.
The anti-HLA Class I antibody was detected in one
RCC, and the anti-granulocyte antibody in another
RCC, both of which were derived from the male
donors.Thecross-matchtestoflymphocytesofpatient
1 and the donors anti-HLA-positive serum indicated
negativity for anti-human immunoglobin-lymphocyte
cytotoxicitytest(AHG-LCT).Moreover,theantibody
specificities determined by LAT-1240 were for A1 and
A36, whereas the patients HLA types were A24/26,
B54/62 and Cw1/9. In contrast, the anti-granulocyte
antibody was reactive with all the 12 antigen panels.
Antibodies to HLA Classes I and II, and granulo-
cytes were detected in the serum of patients 2, and
antibodies to HLA Classes I andII in thatof patient5.
No cross-match test between the patients sera and the
donors lymphocytes could be performed for these
two patients.
DISCUSSION
Our present study showed that the incidences of
ANHTR and the distributions of ANHTR by type
and severity were similar regardless of the gender of
eitherthepatientsorthedonors.However,mostofthe
patients in this study were transfused previously. To
determine whether there is any difference in ANHTR
between male patients with no transfusion history and
female patients, a more intensive study is necessary.
As expected, the positivity rates for anti-HLA
antibodies were significantly higher for females, with
36%forthefemalepatients,13%forthemalepatients,
13% for the female donors and 5% for the male
donors. These were comparable with those of other
reports. Densmore et al. reported that the positivity
rates for anti-HLA antibodies for female apheresis
Severity
Type of
reaction HLA I HLA II Granulo Platelet Severity
Type of
reaction HLA I HLA II Granulo Platelet
Febrile
Anaphylaxis
Dyspnoea unclassified
Anaphylaxis
Severe Dyspnoea unclassified
TRALI
Female donors Male donors
Non-
severe
Allergy
Non-
severe
Allergy
Anaphylactoid
Anaphylactoid
Febrile
Severe
Fig. 2. Antibodiesdetectedinfemaleandmaledonors.Eachhorizontalrowshowsthescreeningresultforonedonor.Greycells
indicatethattheantibodywaspositive,andnon-colouredcellsindicatethattheantibodywasnegative.HLA-I,anti-HLAClassI
antibody; HLA-II, anti-HLA Class II antibody; granulo, anti-granulocyte antibody; platelet, anti-platelet antibody.
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parity (Densmore et al., 1999) and Bray et al. (2004)
showed that anti-HLA antibodies were detected in
22%ofbloodcomponentsbyFlowPRA.Uhrynowska
and Zupanska (1996) found that the positivity rate for
the anti-HLA antibody was 21 3% for patients who
undergo frequent platelet transfusion. To the best of
our knowledge, however, this is the first comparative
study of patients and donors of both sexes. The 13%
positivity rate of the male patients was same to that of
the female donors, probably owing to previous trans-
fusion for the male patients. Whether 5% positivity
rate of the male donors is higher than that of the
normal male population, the screening of male donors
not associated with ANHTR appears necessary.
However,thepositivityratefortheanti-granulocyte
antibody did not differ significantly, not only between
the male and female patients, but also between the
patients and the donors. The positivity rates for the
anti-granulocyte antibody were 13% for the female
patients, 7% for the male patients, 8% for the female
donors and 7% for the male donors. The 13%
positivity rate of the female patients was comparable
to that reported by Clay et al.;1 2  6% of postpartum
women show granulocyte agglutinating antibodies
(Clay et al., 1984). The 7% positivity rate of the male
patients was comparable to that of the female donors
in our study. However, 7% positivity rate of the male
donors was unexpectedly high, because blood donors
in Japan should have no transfusion history; thus,
a much lower incidence is expected. We used the EG-
MPHA method indicated in Materials and Methods.
Althoughtheinfluenceofanti-HLAantibodiesshould
be of concern, seven (77 8%) of the nine anti-
granulocyte-antibody-positive male donors had nei-
thertheanti-HLAnoranti-plateletantibody,asshown
in Fig. 2, suggesting that the detected antibodies bind
to granulocyte antigens other than HLA. Although
anti-leukocyteantibodieshavelong been implicatedin
febrile reactions, our results showed no clear associ-
ation between them.
No significant differences in the positivity rate for
anti-platelet antibody, 9% for female patients, 5% for
male patients, 4% for female donors and 2% for male
donors, were observed between females and males.
Although reports on the anti-platelet antibody in trans-
fusion patients are few, Uhrynowska and Zupanska
(1996) detected the anti-platelet antibody in 9 6%
of sera from platelet-transfused patients using the
platelet suspension immunofluorescence test and the
monoclonal antibody immunobilization of platelet
antigens(MAIPA)technique;thisresultiscomparable
to that of our female patients. We used a commercial
HPA-MPHA kit indicated in Materials and Methods.
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be of concern, all the three anti-platelet-antibody-
positive male donors were anti-HLA-negative, as
shown in Fig. 2. Interestingly, the anti-platelet anti-
body appears to be associated with allergic reactions.
Although reports of anti-platelet antibody-associated
ANHTR otherthan platelet transfusion refractoriness
arefew,Morishitaetal.(2005)reportedacaseofsevere
anaphylactic-like reaction (hypotension, chest tight-
ness and nausea) followed by thrombocytopenia after
the transfusion of FFP containing an anti-CD36
(NaK
a) isoantibody, which was detected using the
HPA-MPHA kit, the same kit that we used.
In this study, only five of the 26 cases of post-
transfusion respiratory reactions could be classified
as TRALI. The remaining 21 cases had to be
classified as Dyspnoea-unclassified,b e c a u s eo ft h e
absence or inadequacy of chest radiographic data
and/or incompatible clinical findings. Table 5 shows
that three of the five (60%) TRALI cases, two
patients and two donors, showed anti-leukocyte
(HLAand/or granulocyte)antibodies.The positivity
r a t ef o ra n t i b o d i e so fT R A L Ic a s e sw a ss i m i l a rt o
that reported by the JRC, in which the positivity rate
was 54 3% (32 3 %f o rp a t i e n t sa n d2 7  7% for
donors) (JRC Transfusion Information 0403-81);
however, the positivity rates in the literature, of
mostly donors, range from 3 6% (Silliman et al.,
2003)to89%(Popovsky&Moore,1985).Forpatient
1 in Table 5, 2 of the 12 suspected donors showed
positivity for the anti-HLA or anti-granulocyte
antibody. The anti-granulocyte antibody was reac-
tive with all the antigen panels, suggesting reactivity
with commonly expressed granulocyte antigen(s);
thus, it may be implicated in TRALI. Unexpectedly,
both donors were male, in contrast with that in the
literature showing that most of donors implicated in
TRALI are female and predominantly multiparous
(Popovsky & Moore, 1985; Davoren et al., 2003;
Kopko et al., 2003; Wallis et al., 2003). Our present
study showed no female donor predominance in
either TRALI or other ANHTRs. In addition, the
positivity rates for antibodies to HLA, granulocytes
and/or platelets in the male donors were unexpect-
edly high. At present, we cannot explain these results
accurately. Further study is necessary.
A two-event model has been proposed for the
aetiology of TRALI, the first event being the clinical
condition of the patients and the second the trans-
fusionofabiologicalresponsemodifier(Sillimanetal.,
2005).OurresultsshowedthatallthefiveTRALIcases
had risk factors for ALI, such as cardiac surgery and
pneumonia, thus supporting the two-event model to
some extent.
The standardization of assays also appears neces-
sary. For anti-HLA antibodies, commercially avail-
able extracted panel antigens have come into
widespread use (Worthington et al., 2001; Insunza
et al., 2004; Sato et al., 2005; Mihaylova et al., 2006).
For anti-platelet antibody screening, the commercial
HPA-MPHA kit described in Materials and Methods
has been widely used in Japan with acceptable
reproducibility (Shibata et al., 1986; Ohto et al.,
2004; Morishita et al., 2005, Morita et al., 2006).
Although the method is as sensitive as MAIPA, and
can be more easily manipulated, large-scale study to
comparewithstandardmethodsisnecessarytomakeit
a standard method worldwide. The screening for the
anti-granulocyteantibodyismoredifficult,becauseno
commercialkitisavailableyetandinmostlaboratories
the preparation of fresh leukocytes is necessary for
each assay (Lucas et al., 2002; Insunza et al., 2004;
Stroncek, 2004). Our use of the EG-MPHA method
facilitated the screening for the anti-granulocyte anti-
bodybecausetheextractedgranulocyteantigenscould
be frozen and stored for a long period and could be
used simply by thawing (Araki et al., 1999; Tanaka
et al., 2000; Han et al., 2006). To make it a standard
assay, however, a large-scale preparation of panel
antigens,aswellasalarge-scalestudy tocompare with
other methods is necessary (Stroncek, 2004).
To summarize, no significant association of
ANHTR with gender, not only for patients, but also
for donors, was shown in our study. Although an-
tibodies to granulocytes, platelets and HLA may be
associated with severe ANHTRs, including TRALI,
alarge-scalestudybasedoncommoncriteriaandusing
standardized assays is necessary to obtain more
detailed information.
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